Published in Int J Inflam on February 21, 2013
Sirolimus for Advanced Age-Related Macular Degeneration (SIRGA2) | NCT01445548
Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy | NCT00695318
Infliximab reduces Zaprinast-induced retinal degeneration in cultures of porcine retina. J Neuroinflammation (2014) 0.78
Anthocyanin can arrest the cone photoreceptor degeneration and act as a novel treatment for retinitis pigmentosa. Int J Ophthalmol (2016) 0.76
The transcorneal electrical stimulation as a novel therapeutic strategy against retinal and optic neuropathy: a review of experimental and clinical trials. Int J Ophthalmol (2016) 0.75
Pathogen recognition and innate immunity. Cell (2006) 44.14
Complement factor H polymorphism in age-related macular degeneration. Science (2005) 31.10
Global data on visual impairment in the year 2002. Bull World Health Organ (2004) 28.05
Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature (2006) 24.43
The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell (2002) 20.11
Complement factor H variant increases the risk of age-related macular degeneration. Science (2005) 17.95
Complement factor H polymorphism and age-related macular degeneration. Science (2005) 17.79
Global estimates of visual impairment: 2010. Br J Ophthalmol (2011) 11.41
AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature (2009) 10.83
An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res (2001) 8.38
Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet (2006) 8.33
Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet (2006) 6.89
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet (2009) 6.71
Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A (2002) 6.47
The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature (2011) 6.21
Age-related macular degeneration. Lancet (2012) 4.17
A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet (2006) 3.96
Restoration of vision after transplantation of photoreceptors. Nature (2012) 3.91
DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature (2011) 3.90
Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci (1998) 3.62
Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology (2004) 3.53
Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait. Nat Rev Genet (2010) 3.20
Age-related macular degeneration--emerging pathogenetic and therapeutic concepts. Ann Med (2006) 2.99
DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell (2012) 2.81
Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration. Exp Eye Res (2003) 2.73
NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med (2012) 2.49
Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu Rev Genomics Hum Genet (2009) 2.40
Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. Mol Aspects Med (2012) 2.37
Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol (2012) 2.28
Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment. Invest Ophthalmol Vis Sci (2011) 2.14
Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin Experiment Ophthalmol (2012) 2.03
Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology (2007) 1.90
Macrophages related to Bruch's membrane in age-related macular degeneration. Eye (Lond) (1990) 1.87
The retinal pigment epithelium in health and disease. Curr Mol Med (2010) 1.87
Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood (2011) 1.82
Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol (2011) 1.76
The dynamic nature of Bruch's membrane. Prog Retin Eye Res (2009) 1.71
The dexamethasone drug delivery system: indications and evidence. Adv Ther (2011) 1.67
A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest Ophthalmol Vis Sci (2009) 1.54
Identification of sequential events and factors associated with microglial activation, migration, and cytotoxicity in retinal degeneration in rd mice. Invest Ophthalmol Vis Sci (2005) 1.48
Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A (2011) 1.47
Systems-level analysis of age-related macular degeneration reveals global biomarkers and phenotype-specific functional networks. Genome Med (2012) 1.46
Animal models of age related macular degeneration. Mol Aspects Med (2012) 1.39
Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives. Retina (2010) 1.33
Age-related macular degeneration: genetic and environmental factors of disease. Mol Interv (2010) 1.24
Laboratory evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology (2012) 1.24
Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv (2008) 1.24
Prevention of age-related macular degeneration-like retinopathy by rapamycin in rats. Am J Pathol (2012) 1.22
Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology (2012) 1.20
Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily. Immunol Res (2011) 1.19
Lipofuscin and N-retinylidene-N-retinylethanolamine (A2E) accumulate in retinal pigment epithelium in absence of light exposure: their origin is 11-cis-retinal. J Biol Chem (2012) 1.18
Current Clinical Trials in Dry AMD and the Definition of Appropriate Clinical Outcome Measures. Semin Ophthalmol (2011) 1.13
Immune regulation in the retina. Immunol Res (2010) 1.12
Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials (2011) 1.10
Animal models of retinal disease. Prog Mol Biol Transl Sci (2011) 1.08
Neuroprotective strategies for the treatment of inherited photoreceptor degeneration. Curr Mol Med (2012) 1.07
Autoimmunity and the retina. II. Raised serum IgM levels in retinitis pigmentosa. Br J Ophthalmol (1973) 1.07
Immune reactivity to different retinal antigens in patients suffering from retinitis pigmentosa. Invest Ophthalmol Vis Sci (1980) 1.05
Mechanisms for countering oxidative stress and damage in retinal pigment epithelium. Int Rev Cell Mol Biol (2012) 1.05
Autoantibodies to retinal astrocytes associated with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (1990) 1.02
Immunological studies in retinitis pigmentosa associated with retinal vascular leakage. Br J Ophthalmol (1978) 1.02
Autoimmunity and the retina. I. Antigenic specificity of photoreceptor cells. Br J Ophthalmol (1970) 1.02
Inflammatory cytokines in aqueous humor of patients with choroidal neovascularization. Mol Vis (2012) 1.02
Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa. Acta Ophthalmol Scand (2005) 1.02
Ciliary neurotrophic factor induces genes associated with inflammation and gliosis in the retina: a gene profiling study of flow-sorted, Müller cells. PLoS One (2011) 1.01
Antiretinal antibodies in serum of patients with age-related macular degeneration. Ophthalmology (1991) 0.99
Intravitreal infliximab and choroidal neovascularization in an animal model. Arch Ophthalmol (2007) 0.97
Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol (2012) 0.93
Serum protein disturbance in retinitis pigmentosa and the association of retinitis pigmentosa with psychosis. Am J Ophthalmol (1962) 0.93
Detection of lymphocytes in the vitreous gel of patients with retinitis pigmentosa. Am J Ophthalmol (1988) 0.90
Expression of HLA-DR antigen on retinal pigment epithelial cells in retinitis pigmentosa. Am J Ophthalmol (1986) 0.89
Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett (2006) 0.87
Qualitative spectral OCT/SLO analysis of drusen change in dry age-related macular degeneration patients treated with Copaxone. J Ocul Pharmacol Ther (2011) 0.86
Review and update of intraocular therapy in noninfectious uveitis. Curr Opin Ophthalmol (2011) 0.85
Age-related macular degeneration is associated with the HLA-Cw*0701 Genotype and the natural killer cell receptor AA haplotype. Invest Ophthalmol Vis Sci (2008) 0.84
Preventing retinal apoptosis--is there a common therapeutic theme? Exp Cell Res (2012) 0.84
Positioning of electronic subretinal implants in blind retinitis pigmentosa patients through multimodal assessment of retinal structures. Invest Ophthalmol Vis Sci (2012) 0.83
Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide. Int J Pharm (2012) 0.81
A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration. Ophthalmologica (2011) 0.81
Homologous retinal outer segment immunization in primates: a clinical and histopathological study. Trans Am Ophthalmol Soc (1974) 0.81
Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab). Can J Ophthalmol (2010) 0.81
Immune complexes in retinitis pigmentosa. Br J Ophthalmol (1984) 0.77
Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q. Am J Hum Genet (2004) 2.70
Short-wavelength light sensitivity of circadian, pupillary, and visual awareness in humans lacking an outer retina. Curr Biol (2007) 2.68
Ciliary targeting motif VxPx directs assembly of a trafficking module through Arf4. EMBO J (2009) 2.34
The C terminus of peripherin/rds participates in rod outer segment targeting and alignment of disk incisures. Mol Biol Cell (2004) 1.58
Characterization of rhodopsin P23H-induced retinal degeneration in a Xenopus laevis model of retinitis pigmentosa. Invest Ophthalmol Vis Sci (2006) 1.45
The role of subunit assembly in peripherin-2 targeting to rod photoreceptor disk membranes and retinitis pigmentosa. Mol Biol Cell (2003) 1.19
Expression of opsin genes early in ocular development of humans and mice. Exp Eye Res (2003) 1.14
Arrestin migrates in photoreceptors in response to light: a study of arrestin localization using an arrestin-GFP fusion protein in transgenic frogs. Exp Eye Res (2003) 1.14
The role of rhodopsin glycosylation in protein folding, trafficking, and light-sensitive retinal degeneration. J Neurosci (2009) 1.11
SNP genome scanning localizes oto-dental syndrome to chromosome 11q13 and microdeletions at this locus implicate FGF3 in dental and inner-ear disease and FADD in ocular coloboma. Hum Mol Genet (2007) 1.10
Mislocalized rhodopsin does not require activation to cause retinal degeneration and neurite outgrowth in Xenopus laevis. J Neurosci (2006) 1.08
Focused magnetic stem cell targeting to the retina using superparamagnetic iron oxide nanoparticles. Cell Transplant (2012) 1.04
Maculopathy due to the R345W substitution in fibulin-3: distinct clinical features, disease variability, and extent of retinal dysfunction. Invest Ophthalmol Vis Sci (2006) 1.04
Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration. Mol Vis (2009) 1.03
Uncoupling of photoreceptor peripherin/rds fusogenic activity from biosynthesis, subunit assembly, and targeting: a potential mechanism for pathogenic effects. J Biol Chem (2004) 0.99
Translational bypass of nonsense mutations in zebrafish rep1, pax2.1 and lamb1 highlights a viable therapeutic option for untreatable genetic eye disease. Hum Mol Genet (2008) 0.98
RD3 gene delivery restores guanylate cyclase localization and rescues photoreceptors in the Rd3 mouse model of Leber congenital amaurosis 12. Hum Mol Genet (2013) 0.96
In situ visualization of protein interactions in sensory neurons: glutamic acid-rich proteins (GARPs) play differential roles for photoreceptor outer segment scaffolding. J Neurosci (2011) 0.95
Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects. J Clin Invest (2013) 0.94
The dependence of retinal degeneration caused by the rhodopsin P23H mutation on light exposure and vitamin a deprivation. Invest Ophthalmol Vis Sci (2009) 0.92
Mesenchymal stem cells and potential applications in treating ocular disease. Curr Eye Res (2010) 0.92
Successful Treatment of Subretinal Neovascularization with Intravitreal Ranibizumab in a Child with Optic Nerve Head Drusen. J Pediatr Ophthalmol Strabismus (2009) 0.90
Transcriptional regulation and expression of the dominant drusen gene FBLN3 (EFEMP1) in mammalian retina. Invest Ophthalmol Vis Sci (2003) 0.90
Targeting of mouse guanylate cyclase 1 (Gucy2e) to Xenopus laevis rod outer segments. Vision Res (2011) 0.87
First genomic localization of oculo-oto-dental syndrome with linkage to chromosome 20q13.1. Invest Ophthalmol Vis Sci (2002) 0.86
Single choroideremia gene in nonmammalian vertebrates explains early embryonic lethality of the zebrafish model of choroideremia. Invest Ophthalmol Vis Sci (2008) 0.86
Pax2 regulates a fadd-dependent molecular switch that drives tissue fusion during eye development. Hum Mol Genet (2012) 0.85
Gene networks: dissecting pathways in retinal development and disease. Prog Retin Eye Res (2012) 0.85
Differentiation of human embryonic stem cells using size-controlled embryoid bodies and negative cell selection in the production of photoreceptor precursor cells. Tissue Eng Part C Methods (2013) 0.83
Familial Bell's palsy in females: a phenotype with a predilection for eyelids and lacrimal gland. Orbit (2005) 0.83
Dysmorphic photoreceptors in a P23H mutant rhodopsin model of retinitis pigmentosa are metabolically active and capable of regenerating to reverse retinal degeneration. J Neurosci (2012) 0.82
CRX controls retinal expression of the X-linked juvenile retinoschisis (RS1) gene. Nucleic Acids Res (2008) 0.82
Characterization of the genomic and transcriptional structure of the CRX gene: substantial differences between human and mouse. Genomics (2002) 0.82
Controlled rod cell ablation in transgenic Xenopus laevis. Invest Ophthalmol Vis Sci (2008) 0.80
Non-invasive anterior segment and posterior segment optical coherence tomography and phenotypic characterization of aniridia. Can J Ophthalmol (2011) 0.80
Foxf2: a novel locus for anterior segment dysgenesis adjacent to the Foxc1 gene. PLoS One (2011) 0.80
Fourier domain optical coherence tomography as a noninvasive means for in vivo detection of retinal degeneration in Xenopus laevis tadpoles. Invest Ophthalmol Vis Sci (2009) 0.79
Pharmacological enhancement of ex vivo gene therapy neuroprotection in a rodent model of retinal degeneration. Ophthalmic Res (2011) 0.78
Gene-specific differential response to anti-apoptotic therapies in zebrafish models of ocular coloboma. Mol Vis (2011) 0.78
Efficient Production of Photoreceptor Precursor Cells from Human Embryonic Stem Cells. Methods Mol Biol (2016) 0.77
Generation of transgenic X. laevis models of retinal degeneration. Methods Mol Biol (2013) 0.77
Gene structure and tissue expression of human selenoprotein W, SEPW1, and identification of a retroprocessed pseudogene, SEPW1P. Biochim Biophys Acta (2003) 0.77
Nonsense suppression therapies in ocular genetic diseases. Cell Mol Life Sci (2015) 0.76
Xenopus laevis tadpoles can regenerate neural retina lost after physical excision but cannot regenerate photoreceptors lost through targeted ablation. Invest Ophthalmol Vis Sci (2013) 0.76
Light Induces Ultrastructural Changes in Rod Outer and Inner Segments, Including Autophagy, in a Transgenic Xenopus laevis P23H Rhodopsin Model of Retinitis Pigmentosa. Invest Ophthalmol Vis Sci (2015) 0.76
Replacing the Amsler grid. Ophthalmology (2005) 0.75
Use of magnetism to enhance cell transplantation success in regenerative medicine. Regen Med (2013) 0.75